Liftstream is an executive search recruitment company in the life sciences sector
Prosensa begins FDA submission process for DMD drug
Authored by James Sheppard
Rare Disease Biotech Summit plc Appoints Erik Ostrowski as CFO
Authored by James Sheppard
PTC Therapeutics appoints Chief Medical Officer and communicates CHMP conditional decision
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Ariad, Ataluren, Chief Medical Officer, CHMP, DMD, Duchenne, Duchenne Muscular Dystrophy, EMA, europe, GSK, Iclusig, investors, MAA, market authorisation application, Murad Husain, oncology, parents, patients, phase III clinical trial, Prosensa, PTC Therapeutics, Rober J. Spiegel, Sarepta, USA, VP Global Regulatory Affairs
Leave a comment
Liftstream Attending World Orphan Drug Congress in Geneva
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Cydan, David Mott, Duchenne Muscular Dystrophy, funding, Liftstream, NEA, Orphan drugs, Prosensa, PTC Therapeutics, public private funding, Rare Disease, Sarepta, Shire, Summit, venture capital, Viropharma, WODC, world orphan drug congress
Leave a comment
Liftstream Life Science Newsletter August Edition
The August edition of the newsletter contains
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market
Tagged Audentes Therapeutics, august, big pharma, biotechnology, bioValley, CEO, Cluster, Duchenne Muscular Dystrophy, Inflection bioscience, Ipsen, Karl Simpson, Liftstream, Liftstream Newsletter, managing conflict, Michael O'Neill, pharmaceutical, start up, Syntaxin, venture capital, venturing financing
1 Comment
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abingworth Management, BioPharma America, Biotechnology cluster, Boston, Brookside Capital, Cristina Csimma, Cydan, David Mott, Deerfield, DELPHI, Dicer Substrate siRNA, Dicerna Pharmaceuticals, drug delivery technologies, Duchenne Muscular Dystrophy, EDI200, Edimer Pharmaceuticals, EnCore™, exon skipping, Exportin-1, Forsite Capital Management, Genzyme, Inhibitors of Nuclear Export, innovation, investors, Karyopharm Therapeutics, Massachusetts, Neil Kirby, New Enterprise Associates, New Leaf Venture Partners, NEZ, Omega Funds, oncology market, Orphan Drug, Prosensa, RA Capital, Rare Disease, Sanofi, Series B, SR One, Third Rock Ventures, TKT, undruggable disease, Vertex Pharmaceuticals, X-linked Hypohidrotic Ectodermal Dysplasia, XLHED
Leave a comment
Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Amsterdam Biotech, Ataluren, Charity, clinical, DART Therapeutics, DMD, Drisapersen, Duchenne Muscular Dystrophy, Eteplirsen, FDA, Gene Williams, Glynn Edwards, GSK, GSK/Prosensa, HT-100, IPO, Market Access, NASDAQ, Netherlands, Orphan drugs, Oxford Biotech, phase II studies, Priority Review, Prosensa, PTC Therapeutics, Rare Disease, regulatory affairs, research and development, Sarepta Therapeutics, Save our Sons, SMT C1100, Summit plc, UK, USA, Utrophin, utrophin modulation
2 Comments
Biotech IPO fever spreads from West to East
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Ataluren, Biopolis, cardiomyocytes, derived neurons, DMD, Duchenne Muscular Dystrophy, Human iPSC, Institute of Medical Sciences, IPO, Japan, JASDAQ, Kyoto University, Malaysia Biotech, New Zealand Biotech, Prof. Hiromitsu Nakauchi, Prof. Norio Nakatsuji, PTC Therapeutics, ReproCELL, Stem Cell, University of Tokyo
Leave a comment
Kurma Life Science Partners Launches new Biotech Fund for Rare Diseases
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Avalon Ventures, BLiNK, CDC Enterprise, DMD, Duchenne Muscular Dystrophy, European Research Institutes, France, GSK, Idinvest Partners, KLS Partners, Kurma, Kurma Biofund, Kurma Life Science Partners, NEA, New Enterprise Associates, oncology, Orphan drugs, partnering, Prosensa, rare diseases, VC, venture capital
Leave a comment